Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31739903 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL2601624 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL31272433 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL31169528 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL12105257 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL30987651 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL2605610 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL13866573 | 1.00 | PTPN1 (0.37) | PTPN1MMP2ANPEPCHRM2CHRM1 | |
| SCHEMBL1785924 | 0.91 | MAPK1 (0.38) | CHRM2CHRM1CHRM3NR1H2MAPK1 | |
| SCHEMBL8354068 | 0.91 | MAPK1 (0.38) | CHRM2CHRM1CHRM3NR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200155527-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-05-21 | — | — | US | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100041697-A1 | PNEUMONIA TREATMENT | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-02-18 | — | — | US | disclosed |
| US-20100041697-A1 | PNEUMONIA TREATMENT | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-02-18 | — | — | US | disclosed |
| US-20100004282-A1 | TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-01-07 | — | — | US | disclosed |
| US-20100004282-A1 | TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002415-A1 | TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-01-07 | — | — | WO | disclosed |
| US-7528264-B2 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | PTPN1 501/4885MMP2 4340/4885ANPEP 640/4885 |
| US-20200155527-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | PTPN1 501/4885MMP2 4340/4885ANPEP 640/4885 |
| US-20100041697-A1 | PNEUMONIA TREATMENT | NQO2, IFNG, PML | PTPN1 3327/4885MMP2 1714/4885ANPEP 920/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | PTPN1 501/4885MMP2 4340/4885ANPEP 640/4885 |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | PIM2, PIM1, PIM3 | PTPN1 501/4885MMP2 4340/4885ANPEP 640/4885 |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | NQO1, NQO2, POR | PTPN1 4507/4885MMP2 4681/4885ANPEP 3259/4885 |
| US-20100004282-A1 | TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION | MRPL19, FOSB, MGAM | PTPN1 444/4885MMP2 401/4885ANPEP 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.